May 20th, 2022 - Read Now Pharmacist Impact on Access to Care in an Epilepsy Clinic MRI Protocols for Veterans With Multiple Sclerosis Neuroimaging in the Era of Artificial Intelligence Autonomic Dysfunction in CADASIL Syndrome.

May 19th, 2022 - More teenagers in the United States reported cannabis use with vaping in 2019, compared with 2017, while cannabis use without vaping declined, based on annual survey data from more than 50,000 teens. “With vaping prevalence rising so quickly among teens, getting a clearer picture of how cannabis use is shifting helps inform prevention and cessation efforts,” corresponding author Noah T.

May 19th, 2022 - On the basis of history and presentation, this patient's psoriatic disease has probably evolved to psoriatic arthritis mutilans (PAM). PAM is considered the most severe form of psoriatic arthritis (PsA), causing joint destruction and functional disability.

May 19th, 2022 - Patients who have histologically active ulcerative colitis (UC) with a Mayo endoscopic subscore (MES) of 1 and a history of steroid use may be at increased risk for clinical relapse, according to a new single-center, retrospective analysis. In recent years, treat-to-target approaches in UC have incorporated clinician and patient-reported outcomes, along with endoscopic remission, defined as MES.

May 19th, 2022 - A few years ago I tracked down my medical school interviewer to thank him for giving me the opportunity to do what I felt I was called to do. I was surprised that, after 15 years, he actually remembered me and remembered details like walking to the courtyard to meet my father who’d driven me to the interview.

May 19th, 2022 - Recently, some liberal colleagues urged a boycott of a conference in Orlando, Fla. , because of various actions by its Republican state governor.

May 19th, 2022 - Meghan Block of Weymouth, Mass. , starts her search at 5 a.

May 19th, 2022 - Several years have passed since I stood among a cohort of eager medical students wearing regalia that signaled a new beginning. Four years of grueling study culminated in a cacophony of unified voices, each reciting a pledge that I had longed to take since early adolescence.

May 19th, 2022 - That Toxoplasma gondii looks good on you Parasite and attractiveness don’t usually go together, but it appears that nobody told Toxoplasma gondii. The world’s most successful parasite affects 30%-50% of the world’s population, and it’s mainly thought to go after the brain in humans, possibly changing behavior and leading to neurological disorders and mental illness.

May 19th, 2022 - Microscopic evaluation of a dermoscopy-guided skin scraping revealed that this was a case of scabies. Classically, patients with scabies have many excoriated papules or plaques on their hands, genitals, and trunk with itching so intense that their sleep is interrupted.

May 19th, 2022 - AUGUSTA, Ga. (May 19, 2022) – A test for the common blood cancer multiple myeloma also holds clear clues that the patient has one of the most uncommon and deadly forms of this cancer, investigators say. While there is a specific test for this rare IgD multiple myeloma, the clues from standard testing are sufficient to rapidly initiate aggressive treatment to reduce or prevent kidney destruction...

May 19th, 2022 - Adding cranberries to your diet could help improve memory and brain function, and lower ‘bad’ cholesterol – according to new research from the University of East Anglia (UK). A new study published today highlights the neuroprotective potential of cranberries. The research team studied the benefits of consuming the equivalent of a cup of cranberries a day among 50 to 80-year-olds. They hope that...

May 18th, 2022 - Key clinical point: Patients with left-sided breast cancer (BC) who received radiation doses to the left anterior descending artery (LAD) experienced an elevated risk for adverse cardiac outcomes. Major finding: Mean dose to LAD was associated with an increased risk for any cardiac event (hazard ratio [HR] 1.

May 18th, 2022 - Key clinical point: Young age at diagnosis of human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (BC) was not associated with any detrimental prognostic value and had no effect on the efficacy of adjuvant dual anti-HER2 targeted therapy. Major finding: Young age had no effect on invasive disease-free survival (adjusted hazard ratio [aHR] 1.

May 18th, 2022 - Key clinical point: Age, tumor subtype, surgery, and brain metastasis are independent risk factors for survival in male patients with breast cancer (BC) and bone metastases and should be considered when devising a treatment strategy. Major finding: Overall survival (OS) and cancer-specific survival (CSS) were significantly lower in patients aged >60 years (hazard ratio [HR] 1.

May 18th, 2022 - Key clinical point: A breast cancer (BC) diagnosis within 5 years of childbirth (postpartum BC [PPBC]) was associated with worse prognosis than no childbirth prior to diagnosis (nulliparous BC), with the association being strongest in young women diagnosed at the age of <35 years and in those with stage I disease. Major finding: Women diagnosed with nulliparous BC vs.

May 18th, 2022 - Key clinical point : Female sex and progressive forms of multiple sclerosis (MS) are the prognostic factors for worsening lower urinary tract symptoms in patients with MS, with neurogenic lower urinary tract dysfunction being a contributor to disease progression. Major finding: A higher bowel/bladder functional system (FS) score, indicating worsening symptoms and functions, was significantly as.

May 18th, 2022 - Key clinical point: Decreased SARS-CoV-2 antibody level is the major contributor to breakthrough SARS-CoV-2 infection in vaccinated patients with multiple sclerosis (MS) on various disease modifying therapies (DMT), with the third dose significantly reducing the risk for infection. Major finding: After the second vaccine dose, the only significant factor associated with the risk for breakthroug.

May 18th, 2022 - Key clinical point : In ocrelizumab-treated patients with multiple sclerosis (MS), a third SARS-CoV-2 vaccine boosted the T-cell response, but had no additive effect on the maximal T-cell response. Major finding: SARS-CoV-2-specific T-cell response in patients treated with ocrelizumab was comparable to those not treated with disease modifying therapy (DMT) and healthy controls (HC) after the se.

May 18th, 2022 - Key clinical point : Continuous siponimod treatment for up to >5 years showed sustained efficacy and a consistent safety profile in patients with secondary progressive multiple sclerosis (SPMS). Major finding: The risk for 6-month confirmed disability progression (CDP) was 22% lower ( P =.